Vanda Pharmaceuticals (VNDA) Other Working Capital Changes (2013)

Vanda Pharmaceuticals has reported Other Working Capital Changes for 17 years, with the latest figure at $5.8 million in Q1 2026.

• Quarterly Other Working Capital Changes rose 7.01% year-over-year to $5.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.4 million (down 11.02% YoY) and the FY2025 annual result came in at $12.1 million, up 77.04% from the prior year.
• Other Working Capital Changes retreated to $5.8 million in Q1 2026 per VNDA's latest filing, from $5.9 million in the prior quarter.
• Over five years, Other Working Capital Changes peaked at $13.4 million in Q1 2022 and troughed at -$11.3 million in Q1 2023.
• A 5-year average of $1.3 million and a median of $1.4 million in 2025 frame the typical range for Other Working Capital Changes.
• The widest YoY moves for Other Working Capital Changes: up 26820.0% in 2022, down 398.11% in 2022.
• Over 5 years, Other Working Capital Changes stood at -$3.4 million in 2022, then plunged by 108.59% to -$7.2 million in 2023, then surged by 150.58% to $3.6 million in 2024, then jumped by 63.43% to $5.9 million in 2025, then slipped by 2.96% to $5.8 million in 2026.
• According to Business Quant data, Other Working Capital Changes over the past three periods registered $5.8 million, $5.9 million, and -$703000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.